Why is ADXN.SW stock falling pre-market today?

ADXN.SW stock is down pre-market due to higher-than-average selling and thin market cap exposure. Elevated volume (**329,067**) versus the 50-day average suggests position adjustment or reaction to company-specific news rather than sector weakness.

What is Meyka AI’s forecast for ADXN.SW stock?

Meyka AI's forecast model projects **monthly CHF0.05**, **quarterly CHF0.10**, and **yearly CHF0.04104**. These are model-based projections and not guarantees; the yearly figure implies about **-18.56%** from the current **CHF0.0504** price.

What are the main risks for ADXN.SW stock holders?

Key risks include clinical trial setbacks, funding needs and potential dilution, limited revenue, and low market cap liquidity. Addex’s negative EPS (**-0.06**) highlights continued development-stage losses.

What price levels should traders watch for ADXN.SW stock?

Traders should watch the year low **CHF0.0472**, short-term resistance near **CHF0.0550**, and the base target **CHF0.0600**. Breaks below **CHF0.0472** could signal further downside; strong news could push toward **CHF0.10**.

CH Stocks

Pre-market top loser: ADXN.SW Addex down 9.03% to CHF0.0504: outlook

ByHuzaifa Zahoor January 27, 2026

Pre-market trading shows ADXN.SW stock sliding 9.03% to CHF0.0504, marking it among the top losers on the SIX exchange this session. The move follows a heavier-than-average volume of 329,067 shares versus a 50-day average of 176,328, signaling active selling. Addex Therapeutics Ltd (ADXN.SW) remains a small-cap biotech with negative EPS (-0.06) and a market cap near CHF7.60 million, so volatility is expected. We review valuation, technical setup, catalysts, and Meyka AI’s forecast to frame near-term risk and opportunity.